Analysts See $-0.01 EPS for HLS Therapeutics Inc. (HLS)

November 10, 2018 - By Jeanette Kaplan

Analysts expect HLS Therapeutics Inc. (CVE:HLS) to report $-0.01 EPS on November, 21.After having $-0.03 EPS previously, HLS Therapeutics Inc.’s analysts see -66.67 % EPS growth. The stock decreased 0.06% or $0.01 during the last trading session, reaching $16.09. About 111,475 shares traded or 86.68% up from the average. HLS Therapeutics Inc. (CVE:HLS) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. The company has market cap of $439.73 million. It is focused on treatment products for the central nervous system and cardiovascular specialties. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: